title: Antibody engineering and modification technologies.
abstract: Antibody engineering has become a well-developed discipline, encompassing discovery methods, production strategies, and modification techniques that have brought forth clinically investigated and marketed therapeutics. The realization of the long-standing goal of production of fully human monoclonal antibodies has focused intensive research on the clinical employment of this potent drug category. However, antibodies are large macromolecules that pose numerous challenges in formulation, optimal pharmacokinetics, manufacturing, stability, and process development. While further improvements in discovery technologies, such as phage display, ribosome display, and transgenic animals continue to advance our capacity to rapidly screen and refine optimal binding molecules, antibody engineers have recently focused more of their efforts on improving protein production and stability, as well as engineering improved biological properties in the effector domains of monoclonal antibodies. A second long-standing goal of antibody engineering, the development of targeted drugs, has not been wholly realized, but this obvious application for antibodies is currently undergoing increasing exploration. Minimal binding proteins, such as Fab, scFv, and single variable domains are the preferred targeting elements for some investigational drugs, whereas non-immunoglobulin scaffold proteins have been explored as binding proteins in other designs. The necessity to utilize non-protein components in targeted drugs, such as polymers, linkers, and cytotoxics, has brought a convergence of the fields of bioconjugate chemistry and protein engineering in experimental antibody therapeutics.
authors.affiliation: Enzon Pharmaceuticals, Piscataway, NJ 08854-3969, USA. david.filpula@enzon.com
authors.forename: David
authors.initials: D
authors.lastname: Filpula
mesh_terms: D000906:Antibodies / Q000737:chemistry* / Q000276:immunology* / Q000302:isolation & purification; D001709:Biotechnology / Q000379:methods*; D016503:Drug Delivery Systems / Q000379:methods*; D015195:Drug Design; D015202:Protein Engineering / Q000379:methods*
chemical_list: D000906:Antibodies